DRUG METABOLISM IN THE BRAIN AND HOW IT CAN ALTER DRUG RESPONSE

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S40, 2014 Special supplement with the abstract book of LATINFARMA 2013 Plenary Lecture PL 006: DRUG METABOLISM IN THE BRAIN AND HOW IT CAN ALTER DRUG RESPONSE Tyndale R. Toronto, Canada. Abstract The brain has a unique expression profile of drug and toxin metabolizing cytochrome P450 enzymes (CYPs); multiple … Continue reading DRUG METABOLISM IN THE BRAIN AND HOW IT CAN ALTER DRUG RESPONSE

J Pharm Pharmacogn Res 2(Suppl. 1): S40, 2014

Special supplement with the abstract book of LATINFARMA 2013

Plenary Lecture

PL 006: DRUG METABOLISM IN THE BRAIN AND HOW IT CAN ALTER DRUG RESPONSE

Tyndale R.

Toronto, Canada.
Abstract

The brain has a unique expression profile of drug and toxin metabolizing cytochrome P450 enzymes (CYPs); multiple forms of CYPs have been identified in the brains of different species including rodents, dogs, monkeys and humans. These CYPs are genetically polymorphic, similar to their expression in the liver meaning some people have high levels, while other people have no expression. These CYPs are uniquely expressed and regulated in a cell and brain-region specific manner and can metabolize many centrally relevant compounds including centrally acting drugs, neurotoxins and neurotransmitters. Drugs and toxins that act on the central nervous system (CNS) may be metabolized in situ in the brain, and differences in in situ metabolism may contribute to variation in an individual’s response to drugs and toxins. Studies in artificial in vitro systems, with added cofactors, indicate that brain CYPs have similar substrate specificity and in vitro kinetics to their hepatic forms. We have shown that brain CYPs are metabolically active in situ using a radio-labeled suicide inhibitor, which takes advantage of the brain CYP metabolic activity of the animal, injected directly into the brain of a living rat. We have also subsequently demonstrated in vivo, using a similar brain inhibitor or induction approach, that enzymes within the brain can alter drug effect. This is illustrated using CYP2B inactivation of the anesthetic propofol within the rat brain and its resulting impact on sedation, CYP2B activation of a neurotoxic pesticide chlorpyrifos and its alteration of neurotoxicity. Likewise we have shown that brain CYP2D activation of codeine to morphine is important to the early time points for analgesia, and that brain CYP2D may importantly alter risk for Parkinson’s disease through its ability to inactivate neurotoxins such as MPTP. These results indicate that brain CYPs are actively able to metabolize CNS acting drugs and neurotoxins and can contribute significantly to local drug response. The induction of brain CYPs by nicotine and alcohol, and higher levels in the brains of smokers and alcoholics, suggests that in addition to pharmacogenetic variation, commonly used drugs could also alter responses to centrallyacting drugs and toxins. More broadly these studies indicate that brain CYPs are active in situ and have sufficient local enzymatic activity to meaningfully alter the pharmacology of centrally acting drugs and neurotoxins.

Ageratum conyzoides and eggshell membrane hydrolysates in chronic inflammation
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 972-993, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres24.1956_12.5.972 Original Article Anti-inflammatory effect of the mixture of Ageratum conyzoides L. extract and eggshell membrane hydrolysates and in silico active compound predictions [Efecto antiinflamatorio de la mezcla de extracto de Ageratum conyzoides L. e hidrolizados de membrana de cáscara de huevo, … Continue reading Ageratum conyzoides and eggshell membrane hydrolysates in chronic inflammation
SS-31 for diabetic nephropathy
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 956-971, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres23.1904_12.5.956 Review SS-31 protects diabetic nephropathy progression: A systematic review of in vivo and in vitro studies [El SS-31 protege la progresión de la nefropatía diabética: Una revisión sistemática de estudios in vivo e in vitro] Jonathan Christianto Sutadji1#, Dian Anggraini Permatasari … Continue reading SS-31 for diabetic nephropathy
Hypertension knowledge and its associated factors in primary care
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 943-955, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres24.1955_12.5.943 Original Article Hypertension knowledge and its associated factors among hypertensive patients in primary care settings in Central Vietnam: A cross-sectional study [Conocimiento de la hipertensión y sus factores asociados entre pacientes hipertensos en entornos de atención primaria en el centro de … Continue reading Hypertension knowledge and its associated factors in primary care

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio